Suppr超能文献

Fbxl18将LRRK2靶向蛋白酶体降解并减轻细胞毒性。

Fbxl18 targets LRRK2 for proteasomal degradation and attenuates cell toxicity.

作者信息

Ding Xiaodong, Barodia Sandeep K, Ma Lisha, Goldberg Matthew S

机构信息

Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, The University of Alabama at Birmingham, Birmingham, AL, USA.

出版信息

Neurobiol Dis. 2017 Feb;98:122-136. doi: 10.1016/j.nbd.2016.11.004. Epub 2016 Nov 24.

Abstract

Dominantly inherited mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common causes of familial Parkinson's disease (PD) and LRRK2 polymorphisms are associated with increased risk for idiopathic PD. However, the molecular mechanisms by which these mutations cause PD remain uncertain. In vitro studies indicate that disease-linked mutations in LRRK2 increase LRRK2 kinase activity and LRRK2-mediated cell toxicity. Identifying LRRK2-interacting proteins and determining their effects on LRRK2 are important for understanding LRRK2 function and for delineating the pathophysiological mechanisms of LRRK2 mutations. Here we identified a novel protein, F-box and leucine-rich repeat domain-containing protein 18 (Fbxl18) that physically associates with LRRK2. We demonstrated that Fbxl18 is a component of a Skp1-Cullin1-F-box ubiquitin ligase complex that regulates the abundance of LRRK2 by selectively targeting phosphorylated LRRK2 for ubiquitination and proteasomal degradation. Knockdown of endogenous Fbxl18 stabilized LRRK2 abundance while protein kinase C activation enhanced LRRK2 degradation by Fbxl18. Dephosphorylation of LRRK2 blocked Fbxl18 association with LRRK2. Taken together, we have identified potential mechanisms for LRRK2 regulation by kinase signaling pathways. Furthermore, Fbxl18 prevented caspase activation and cell death caused by LRRK2 and PD-linked mutant LRRK2. This reveals novel targets for developing potential therapies for familial and idiopathic PD.

摘要

富含亮氨酸重复激酶2(LRRK2)中的显性遗传突变是家族性帕金森病(PD)最常见的病因,并且LRRK2基因多态性与特发性PD的风险增加相关。然而,这些突变导致PD的分子机制仍不确定。体外研究表明,LRRK2中与疾病相关的突变会增加LRRK2激酶活性以及LRRK2介导的细胞毒性。鉴定与LRRK2相互作用的蛋白质并确定它们对LRRK2的影响,对于理解LRRK2的功能以及描绘LRRK2突变的病理生理机制很重要。在这里,我们鉴定了一种新的蛋白质,即含F-box和富含亮氨酸重复结构域的蛋白质18(Fbxl18),它与LRRK2发生物理结合。我们证明Fbxl18是Skp1-Cullin1-F-box泛素连接酶复合物的一个组成部分,该复合物通过选择性地将磷酸化的LRRK2靶向泛素化和蛋白酶体降解来调节LRRK2的丰度。敲低内源性Fbxl18可稳定LRRK2的丰度,而蛋白激酶C激活则增强Fbxl18对LRRK2的降解作用。LRRK2的去磷酸化会阻断Fbxl18与LRRK2的结合。综上所述,我们已经确定了激酶信号通路对LRRK2的潜在调控机制。此外,Fbxl18可防止由LRRK2和与PD相关的突变型LRRK2引起的半胱天冬酶激活和细胞死亡。这揭示了开发家族性和特发性PD潜在治疗方法的新靶点。

相似文献

10
LRRK2 Promotes Tau Accumulation, Aggregation and Release.LRRK2 促进 Tau 的积累、聚集和释放。
Mol Neurobiol. 2016 Jul;53(5):3124-3135. doi: 10.1007/s12035-015-9209-z. Epub 2015 May 27.

引用本文的文献

本文引用的文献

1
LRRK2 secretion in exosomes is regulated by 14-3-3.LRRK2 在 exosomes 中的分泌受 14-3-3 的调节。
Hum Mol Genet. 2013 Dec 15;22(24):4988-5000. doi: 10.1093/hmg/ddt346. Epub 2013 Jul 25.
3
Phosphorylation of LRRK2: from kinase to substrate.LRRK2 的磷酸化:从激酶到底物。
Biochem Soc Trans. 2012 Oct;40(5):1102-10. doi: 10.1042/BST20120128.
8
Parkinson's disease: insights from pathways.帕金森病:通路研究的新视角
Hum Mol Genet. 2010 Apr 15;19(R1):R21-7. doi: 10.1093/hmg/ddq167. Epub 2010 Apr 26.
10

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验